Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

A selective inhibitor of the osteoclastic V-H(+)-ATPase prevents bone loss in both thyroparathyroidectomized and ovariectomized rats.

Visentin L, Dodds RA, Valente M, Misiano P, Bradbeer JN, Oneta S, Liang X, Gowen M, Farina C.

J Clin Invest. 2000 Jul;106(2):309-18.

2.

Design and characterization of orally active Arg-Gly-Asp peptidomimetic vitronectin receptor antagonist SB 265123 for prevention of bone loss in osteoporosis.

Lark MW, Stroup GB, Hwang SM, James IE, Rieman DJ, Drake FH, Bradbeer JN, Mathur A, Erhard KF, Newlander KA, Ross ST, Salyers KL, Smith BR, Miller WH, Huffman WF, Gowen M.

J Pharmacol Exp Ther. 1999 Nov;291(2):612-7.

PMID:
10525079
3.

Vis-à-vis cells and the priming of bone formation.

Riminucci M, Bradbeer JN, Corsi A, Gentili C, Descalzi F, Cancedda R, Bianco P.

J Bone Miner Res. 1998 Dec;13(12):1852-61.

4.

Idoxifene: a novel selective estrogen receptor modulator prevents bone loss and lowers cholesterol levels in ovariectomized rats and decreases uterine weight in intact rats.

Nuttall ME, Bradbeer JN, Stroup GB, Nadeau DP, Hoffman SJ, Zhao H, Rehm S, Gowen M.

Endocrinology. 1998 Dec;139(12):5224-34.

PMID:
9832463
5.
6.

Disease-modifying activity of SK&F 106615 in rat adjuvant-induced arthritis. Multiparameter analysis of disease magnetic resonance imaging and bone mineral density measurements.

Bradbeer JN, Kapadia RD, Sarkar SK, Zhao H, Stroup GB, Swift BA, Rieman DJ, Badger AM.

Arthritis Rheum. 1996 Mar;39(3):504-14.

PMID:
8607900
7.

Monoclonal antibodies with selective reactivity against osteoblasts and osteocytes in human bone.

Walsh S, Dodds RA, James IE, Bradbeer JN, Gowen M.

J Bone Miner Res. 1994 Nov;9(11):1687-96.

PMID:
7863819
9.
11.

Giemsa as a fluorescent stain for mineralized bone.

Bradbeer JN, Riminucci M, Bianco P.

J Histochem Cytochem. 1994 May;42(5):677-80.

PMID:
7512588
12.

Evaluation of osteoblastic activity by morphometric comparison of alkaline phosphatase cytochemistry vs. tetracycline fluorescence.

Ballanti P, Bradbeer JN, Bonucci E, Coen G, Mazzaferro S, Bianco P.

Bone. 1993 May-Jun;14(3):321-6.

PMID:
8363875
13.

Marrow stromal (Western-Bainton) cells: identification, morphometry, confocal imaging and changes in disease.

Bianco P, Bradbeer JN, Riminucci M, Boyde A.

Bone. 1993 May-Jun;14(3):315-20. Review. No abstract available.

PMID:
8363874
14.

Human parathyroid peptide treatment of vertebral osteoporosis.

Reeve J, Arlot ME, Bradbeer JN, Hesp R, Mcally E, Meunier PJ, Zanelli JM.

Osteoporos Int. 1993;3 Suppl 1:199-203.

PMID:
8461559
15.

Temporal variations in iliac trabecular bone formation in vertebral osteoporosis.

Arlot ME, Bradbeer JN, Edouard C, Green JR, Hesp R, Roux JP, Meunier PJ, Reeve J.

Calcif Tissue Int. 1993 Jan;52(1):10-5.

PMID:
8453500
16.

Bone remodeling in hip fracture.

Reeve J, Zanelli JM, Garrahan N, Bradbeer JN, Wand JS, Moyes ST, Roux JP, Smith T.

Calcif Tissue Int. 1993;53 Suppl 1:S108-12. Review.

PMID:
8275363
19.

Relationship between the location of osteoblastic alkaline phosphatase activity and bone formation in human iliac crest bone.

Bradbeer JN, Zanelli JM, Lindsay PC, Pearson J, Reeve J.

J Bone Miner Res. 1992 Aug;7(8):905-12.

PMID:
1442204
20.

Bone remodelling does not decline after menopause in vertebral fracture osteoporosis.

Wand JS, Green JR, Hesp R, Bradbeer JN, Sambrook PN, Smith T, Hampton L, Zanelli JM, Reeve J.

Bone Miner. 1992 Jun;17(3):361-75.

PMID:
1623330
21.

Iliac trabecular bone formation predicts radial trabecular bone density changes in type 1 osteoporosis.

Hesp R, Arlot ME, Edouard C, Bradbeer JN, Meunier PJ, Reeve J.

J Bone Miner Res. 1991 Sep;6(9):929-35.

PMID:
1789140
22.

hPTH 1-34 treatment of osteoporosis with added hormone replacement therapy: biochemical, kinetic and histological responses.

Reeve J, Bradbeer JN, Arlot M, Davies UM, Green JR, Hampton L, Edouard C, Hesp R, Hulme P, Ashby JP, et al.

Osteoporos Int. 1991 Jun;1(3):162-70.

PMID:
1790404
23.

Bone resorption and circulating PTH-like bioactivity in an animal model of hypercalcaemia of malignancy.

Mehdizadeh S, Alaghband-Zadeh J, Gusterson B, Arlot M, Bradbeer JN, Loveridge N.

Biochem Biophys Res Commun. 1989 Jun 30;161(3):1166-71.

PMID:
2742581
24.

The metatarsal cytochemical bioassay of parathyroid hormone: validation, specificity, and application to the study of pseudohypoparathyroidism type I.

Bradbeer JN, Dunham J, Fischer JA, Nagant de Deuxchaisnes C, Loveridge N.

J Clin Endocrinol Metab. 1988 Dec;67(6):1237-43.

PMID:
3192680
25.

Certain vitamin D metabolites potentiate the expression of parathyroid hormone bioactivity.

Bradbeer JN, Mehdizadeh S, Fraher LJ, Loveridge N.

J Bone Miner Res. 1988 Feb;3(1):47-52.

PMID:
2850724
26.

Interactions between calciotropic hormones.

Bradbeer JN.

J R Soc Med. 1987 Aug;80(8):478-80.

Supplemental Content

Loading ...
Support Center